Trials / Completed
CompletedNCT00095342
Study Evaluating TMI-005 in Active Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 390 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TMI-005 |
Timeline
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2004-11-03
- Last updated
- 2009-09-10
Locations
8 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00095342. Inclusion in this directory is not an endorsement.